Aspira Pathlab & Diagnostics Schedules Board Meeting for Q2 FY27 Results
Aspira Pathlab & Diagnostics Ltd 路 Intimation 路 06 Nov 2026, 5:30 am
Aspira Pathlab & Diagnostics Schedules Board Meeting for Q2 FY27 Results Aspira Pathlab & Diagnostics Limited announced that its Board of Directors will meet on 6th Nov'26 to consider and approve the un-audited standalone financial results, alongside the limited review report, for the second quarter and half-year ended 30th Sep'26. In compliance with SEBI insider trading regulations, the trading window for dealing in company securities remains closed for designated persons and their immediate relatives until 48 hours following the declaration of the financial results.
Original exchange filing (PDF)
More announcements from Aspira Pathlab & Diagnostics Ltd
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jay Arvind Bhanushali 路 18 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jay Arvind Bhanushali 路 14 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jay Arvind Bhanushali 路 14 Nov 2026
- Enclosed herewith Financial Result for the Half Year ended 30th September 2026 路 06 Nov 2026
- Enclosed herewith Board Meeting Outcomes dated 6th November 2026 路 06 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jay Arvind Bhanushali 路 01 Oct 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jay Arvind Bhanushali 路 28 Sept 2026
- Disclosure of Voting Results of 53rd Annual General Meeting along with the Scrutinizer Report 路 26 Sept 2026
